This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (224)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Nutritional and Metabolic Disorders, Other  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)

Hanna Bloomfield Rubins, MD,MPH; Sander J. Robins, MD; Dorothea Collins, ScD; David B. Nelson, PhD; Marshall B. Elam, MD,PhD; Ernst J. Schaefer, MD; Fred H. Faas, MD; James W. Anderson, MD; for the VA-HIT Study Group

Arch Intern Med. 2002;162:2597-2604.

Background  Diabetes mellitus, impaired fasting glucose level, or insulin resistance are associated with increased risk of cardiovascular disease.

Objectives  To determine the efficacy of gemfibrozil in subjects with varying levels of glucose tolerance or hyperinsulinemia and to examine the association between diabetes status and glucose and insulin levels and risk of cardiovascular outcomes.

Methods  Subgroup analyses from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized controlled trial that enrolled 2531 men with coronary heart disease (CHD), a high-density lipoprotein cholesterol level of 40 mg/dL or less (1.04 mmol/L), and a low-density lipoprotein cholesterol level of 140 mg/dL or less (3.63 mmol/L). Subjects received either gemfibrozil (1200 mg/d) or matching placebo and were followed up for an average of 5.1 years. In this article, we report the composite end point (CHD death, stroke, or myocardial infarction).

Results  Compared with those with a normal fasting glucose level, risk was increased in subjects with known diabetes (hazard ratio [HR], 1.87; 95% confidence interval [CI], 1.44-2.43; P = .001) and those with newly diagnosed diabetes (HR, 1.72; 95% CI, 1.10-2.68; P = .02). In persons without diabetes, a fasting plasma insulin level of 39 µU/mL or greater (271 pmol/L) was associated with a 31% increased risk of events (P = .03). Gemfibrozil was effective in persons with diabetes (risk reduction for composite end point, 32%; P = .004). The reduction in CHD death was 41% (HR, 0.59; 95% CI, 0.39-0.91; P = .02). Among individuals without diabetes, gemfibrozil was most efficacious for those in the highest fasting plasma insulin level quartile (risk reduction, 35%; P = .04).

Conclusion  In men with CHD and a low high-density lipoprotein cholesterol level, gemfibrozil use was associated with a reduction in major cardiovascular events in persons with diabetes and in nondiabetic subjects with a high fasting plasma insulin level.

From the Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, Minneapolis, Minn (Drs Rubins and Nelson); the Department of Medicine, Boston University School of Medicine, Boston, Mass (Dr Robins); the Department of Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, Conn (Dr Collins); the Department of Medicine, Veterans Affairs Medical Center, Memphis, Tenn (Dr Elam); the Lipid Research Laboratory, Tufts University School of Medicine, Boston (Dr Schaefer); the Department of Medicine, Veterans Affairs Medical Center, Little Rock, Ark (Dr Faas); and the Department of Medicine, Veterans Affairs Medical Center, Lexington, Ky (Dr Anderson). A complete list of the members of the VA-HIT Study Group was published previously (N Engl J Med. 1999;341:410-418).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

The Other Side of the Bezafibrate Infarction Prevention Trial Data—Reply
Alexander Tenenbaum, Michael Motro, Enrique Z. Fisman, David Tanne, Valentina Boyko, and Solomon Behar
Arch Intern Med. 2005;165(20):2432.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?
Bitzur et al.
Diabetes Care 2009;32:S373-S377.
FULL TEXT  

Dyslipidemia and cardiovascular risk: the importance of early prevention
Miller
QJM 2009;102:657-667.
ABSTRACT | FULL TEXT  

Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate
Taskinen et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:950-955.
ABSTRACT | FULL TEXT  

Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon
Magee and Sharpe
J. Clin. Pathol. 2009;62:250-253.
ABSTRACT | FULL TEXT  

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Scott et al.
Diabetes Care 2009;32:493-498.
ABSTRACT | FULL TEXT  

PPAR-{alpha} activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway
Bulhak et al.
Am. J. Physiol. Heart Circ. Physiol. 2009;296:H719-H727.
ABSTRACT | FULL TEXT  

Fibrates: where are we now?
Seth Loomba and Arora
Ther Adv Cardiovasc Dis 2009;3:91-96.
ABSTRACT  

Impact of Genetic and Environmental Factors on hsCRP Concentrations and Response to Therapeutic Agents
Shen and Ordovas
Clin. Chem. 2009;55:256-264.
ABSTRACT | FULL TEXT  

Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus
Hiukka et al.
J Am Coll Cardiol 2008;52:2190-2197.
ABSTRACT | FULL TEXT  

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart et al.
Diabetes and Vascular Disease Research 2008;5:319-335.
ABSTRACT  

American College of Endocrinology Pre-Diabetes Consensus Conference: Part Two
Bloomgarden
Diabetes Care 2008;31:2222-2229.
FULL TEXT  

Adipokines--targeting a root cause of cardiometabolic risk
Bakhai
QJM 2008;101:767-776.
ABSTRACT | FULL TEXT  

Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT | FULL TEXT  

Cardiovascular Disease in Diabetes
Bloomgarden
Diabetes Care 2008;31:1260-1266.
FULL TEXT  

Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Cholesterol: The Veterans Affairs HDL Intervention Trial
Robins et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1172-1178.
ABSTRACT | FULL TEXT  

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT | FULL TEXT  

PROactive: time for a critical appraisal
Betteridge et al.
Eur Heart J 2008;29:969-983.
ABSTRACT | FULL TEXT  

From individual risk factors and the metabolic syndrome to global cardiometabolic risk
Despres et al.
Eur Heart J Suppl 2008;10:B24-B33.
ABSTRACT | FULL TEXT  

Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
Goldenberg et al.
J Am Coll Cardiol 2008;51:459-465.
ABSTRACT | FULL TEXT  

Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes
Pedro-Botet
British Journal of Diabetes & Vascular Disease 2008;8:22-27.
ABSTRACT  

Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
Barter and Rye
Arterioscler. Thromb. Vasc. Bio. 2008;28:39-46.
ABSTRACT | FULL TEXT  

Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Steiner
Diabetes and Vascular Disease Research 2007;4:368-374.
ABSTRACT  

The role of fenofibrate in clinical practice
Zambon and Cusi
Diabetes and Vascular Disease Research 2007;4:S15-S20.
ABSTRACT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

Update on Dyslipidemia
Garg and Simha
J. Clin. Endocrinol. Metab. 2007;92:1581-1589.
ABSTRACT | FULL TEXT  

Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets
Lee and Choudhury
Heart 2007;93:559-564.
ABSTRACT | FULL TEXT  

Hypertriglyceridemia: its etiology, effects and treatment
Yuan et al.
CMAJ 2007;176:1113-1120.
ABSTRACT | FULL TEXT  

Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction
Grant and Meigs
Diabetes Care 2007;30:479-484.
ABSTRACT | FULL TEXT  

Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown and Plutzky
Circulation 2007;115:518-533.
ABSTRACT | FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT  

Rational therapy of mixed dyslipidaemia in a patient with diabetes
Reasner
British Journal of Diabetes & Vascular Disease 2007;7:25-30.
ABSTRACT  

Fibrates after the FIELD study: some answers, more questions
Wierzbicki
Diabetes and Vascular Disease Research 2006;3:166-171.
ABSTRACT  

International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik et al.
Pharmacol. Rev. 2006;58:726-741.
ABSTRACT | FULL TEXT  

Multitherapy for diabetes
Menard and Ardilouze
CMAJ 2006;175:1247-1247.
FULL TEXT  

Introduction
Steiner and Chapman
Diabetes and Vascular Disease Research 2006;3:S1-S1.
 

Lipid-lowering therapy in type 2 diabetes: a review of the evidence
Steinmetz
Diabetes and Vascular Disease Research 2006;3:S10-S15.
ABSTRACT  

Reducing vascular risk in the diabetic patient: implications from the FIELD study
Zambon
Diabetes and Vascular Disease Research 2006;3:S16-S20.
ABSTRACT  

Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch
CJASN 2006;1:1090-1099.
ABSTRACT | FULL TEXT  

Exogenous Insulin Use and Hypertension in Adult Patients With Type 2 Diabetes Mellitus.
Tseng
Arch Intern Med 2006;166:1184-1189.
ABSTRACT | FULL TEXT  

Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes
McQueen
Evid. Based Med. 2006;11:86-86.
FULL TEXT  

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Costa et al.
BMJ 2006;332:1115-1124.
ABSTRACT | FULL TEXT  

The role of fibrates in a statin world.
Bloomfield
Arch Intern Med 2006;166:715-716.
FULL TEXT  

Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study.
Tenkanen et al.
Arch Intern Med 2006;166:743-748.
ABSTRACT | FULL TEXT  

Differential Effects of Isoflavones, from Astragalus Membranaceus and Pueraria Thomsonii, on the Activation of PPAR{alpha}, PPAR{gamma}, and Adipocyte Differentiation In Vitro
Shen et al.
J. Nutr. 2006;136:899-905.
ABSTRACT | FULL TEXT  

Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism?
Barter and Rye
Circulation 2006;113:1553-1555.
FULL TEXT  

Review: Fibrates: therapeutic review
Chapman
British Journal of Diabetes & Vascular Disease 2006;6:11-19.
ABSTRACT  

Evolving treatment paradigms for vascular risk reduction in type 2 diabetes: Report of an international symposium held in Barcelona, Spain, January 27-29, 2006
British Journal of Diabetes & Vascular Disease 2006;6:S1-S12.
 

Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia
Reeds et al.
Am. J. Physiol. Endocrinol. Metab. 2006;290:E47-E53.
ABSTRACT | FULL TEXT  

The Other Side of the Bezafibrate Infarction Prevention Trial Data--Reply
Tenenbaum et al.
Arch Intern Med 2005;165:2432-2432.
FULL TEXT  

Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid
Van Gaal et al.
British Journal of Diabetes & Vascular Disease 2005;5:344-350.
ABSTRACT  

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy et al.
Circulation 2005;112:2735-2752.
FULL TEXT  

Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease: The Louis F. Bishop Lecture
Gotto
J Am Coll Cardiol 2005;46:1219-1224.
FULL TEXT  

Second World Congress on the Insulin Resistance Syndrome: Hypertension, cardiovascular disease, and treatment approaches
Bloomgarden
Diabetes Care 2005;28:2073-2080.
FULL TEXT  

Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists
Staels and Fruchart
Diabetes 2005;54:2460-2470.
ABSTRACT | FULL TEXT  

From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes
Mccallum and Fisher
British Journal of Diabetes & Vascular Disease 2005;5:218-225.
ABSTRACT  

Raising HDL-cholesterol and lowering CHD risk: does intervention work?
Shepherd
Eur Heart J Suppl 2005;7:F15-F22.
ABSTRACT | FULL TEXT  

Niaspan(R): a powerful treatment option for 'diabetic dyslipidaemia'
Reasner
Eur Heart J Suppl 2005;7:F48-F55.
ABSTRACT | FULL TEXT  

Strategies for the prevention of type 2 diabetes and cardiovascular disease
Tuomilehto et al.
Eur Heart J Suppl 2005;7:D18-D22.
FULL TEXT  

Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
Tenenbaum et al.
Arch Intern Med 2005;165:1154-1160.
ABSTRACT | FULL TEXT  

Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?
Drexel et al.
Diabetes Care 2005;28:101-107.
ABSTRACT | FULL TEXT  

Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou et al.
ANGIOLOGY 2004;55:589-612.
ABSTRACT  

Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou et al.
ANGIOLOGY 2004;55:589-612.
ABSTRACT  

Nuclear Receptor Signaling and Cardiac Energetics
Huss and Kelly
Circ. Res. 2004;95:568-578.
ABSTRACT | FULL TEXT  

Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'
Chew and Watts
QJM 2004;97:537-548.
ABSTRACT | FULL TEXT  

The Relationship of Fasting Serum Radioimmune Insulin Levels to Incident Coronary Heart Disease in an Insulin-Treated Diabetic Cohort
Kronmal et al.
J. Clin. Endocrinol. Metab. 2004;89:2852-2858.
ABSTRACT | FULL TEXT  

Lipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss
Diabetes Care 2004;27:1496-1504.
ABSTRACT | FULL TEXT  

Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians
Snow et al.
ANN INTERN MED 2004;140:644-649.
ABSTRACT | FULL TEXT  

Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
Vijan and Hayward
ANN INTERN MED 2004;140:650-658.
ABSTRACT | FULL TEXT  

A Novel Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis
Guo et al.
Endocrinology 2004;145:1640-1648.
ABSTRACT | FULL TEXT  

Clinical Trials and Lipid Guidelines for Type II Diabetes
Prisant
J Clin Pharmacol 2004;44:423-430.
ABSTRACT | FULL TEXT  

Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)
Robins et al.
Diabetes Care 2003;26:1513-1517.
ABSTRACT | FULL TEXT  

Gemfibrozil Reduces Plasma C-Reactive Protein Levels in Abdominally Obese Men With the Atherogenic Dyslipidemia of the Metabolic Syndrome
Despres et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:702-703.
FULL TEXT  

Cost-outcome benefits of fibrate therapy in type 2 diabetes
Feher et al.
British Journal of Diabetes & Vascular Disease 2003;3:124-130.
ABSTRACT